U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07456891) titled 'Remibrutinib Open Label Roll-over Post-trial Access Protocol' on March 03.
Brief Summary: Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
Indication of the Parent Protocol
Intervention:
DRUG: Remibrutinib
Remibrutinib film coated tablets i...